← FDA DRUG APPROVALS

FDA ANDA · ANDA215978

SAFINAMIDE MESYLATE

Sponsor: MSN

APPLICATION
ANDA215978
TYPE
ANDA
ORIGINAL APPROVAL
2024-12-31
LATEST ACTION
2024-12-31
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

SAFINAMIDE MESYLATEPrescription
SAFINAMIDE MESYLATE EQ 50MG BASE · TABLET · ORAL
SAFINAMIDE MESYLATEPrescription
SAFINAMIDE MESYLATE EQ 100MG BASE · TABLET · ORAL

Approval history

2024-12-31UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →